Aldreya’s RASP Inhibitor ADX-629 enters phase 2 trial for COVID-19, asthma and psoriasisDecember 27, 2020 0 By FM
The Lexington based biotech firm, Aldeyra Therapeutics has commenced phase II study of its reactive aldehyde species (RASP) inhibitor, ADX-629, for treating COVID-19, atopic asthma and psoriasis.
The single-centre, double-masked, placebo-controlled, crossover phase 2 clinical trial will assess the safety and efficacy of ADX-629 in adult patients with mild asthma induced by bronchial asthma challenge.
Twelve patients with cat or house dust mite allergen-induced asthma will be randomized to receive either 600 mg of ADX-629 or placebo twice daily for approximately one week. Outcomes will include pulmonary function testing following allergen and methacholine challenge, sputum eosinophil counts, and plasma levels of cytokines and RASP. Enrollment is expected to begin in the first quarter of 2021.
The multi-centre, open-label, single-group phase 2 clinical trial will assess the safety and efficacy of ADX-629 in adult patients with mild to moderate plaque psoriasis. Ten adult patients will receive 250 mg of ADX-629 twice daily for up to 90 days. Outcomes will include psoriasis area and severity index, skin cytokine transcription profiles, plasma leukocyte cytokine release following endotoxin-challenge, and plasma levels of cytokines and RASP. Enrollment is expected to begin in the first half of next year.